Quick 2 BaggersSS

[BottomBounce]

$CLNE Clean Energy Fuels Corp Major Holders: http://finance.yahoo.com/q/mh?s=CLNE+Major+Holders

[BottomBounce]

$CLNE Clean Energy Fuels "Refuse
Solid waste trucks: the Clean Energy solution " http://www.cleanenergyfuels.com/products_services/refuse.html

[BottomBounce]

$ECA Encana ~ The DJ Basin is a light oil play with significant scale located in northeast Colorado and extending into Wyoming and Nebraska. For more than 30 years, this area has been one of the country’s most important oil and natural gas producing basins. Encana’s position in the play is located in the heart of the Wattenberg field, the most productive field in the area. Encana produces oil and gas from the Niobrara, Codell and J Sand geologic formations in this field.

This play is ideally situated with no market takeaway constraints. Encana has achieved significant well cost reductions in this play, and oil and condensate which make up 70% of total liquids in the area, generate quality returns for the company. http://www.encana.com/operations/dj-basin.html

[BottomBounce]

$CLNE

[BottomBounce]

$ECA Encana Corporation (Encana) is a North American energy producer. The Company’s other operations include the transportation and marketing of natural gas, oil and natural gas liquids (NGLs). All of Encana’s reserves and production are located in North America. The Company operates in two divisions: Canadian Division and USA Division. The Canadian Division includes the exploration for, development of, and production of natural gas, oil and NGLs and other related activities within Canada. USA Division includes the exploration for, development of, and production of natural gas, oil and NGLs and other related activities within the United States. In May 2014, Jonah Energy LLC acquired Jonah field operations located in Sublette County, Wyoming, from Encana Oil & Gas (USA) Inc., a subsidiary of Encana Corporation.

[BottomBounce]

$ECA Encana ~ The San Juan is a new light sweet oil play located in northwest New Mexico. The primary formation targets in the basin are the Gallup and Mancos silt. Encana has established a significant land position and is currently the dominant operator in the play. Encana continues to reduce well costs and grow its oil production in this play. http://www.encana.com/operations/san-juan.html

[Enterprising Investor]

ALJJ

For the three months ended March 31, 2014, ALJJ posted net income of $3.5 million and earnings per share of $0.11. For the six months ended March 31, 2014, ALJJ posted net income of $4.9 million and earnings per share of $0.16.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102012980

[Xzibit]

ETRM looking good Psi

[Psionic Trader]

holding a small position ETRM in my roth account. out of all other stocks for now. too much uncertainty

[Psionic Trader]

$OCRX chart $9.56 came up on chart scans.

[Psionic Trader]

ADMP should be good... just waiting for it to rebound on NDA news this month.

[Xzibit]

$ADMP

DD Notes ~ http://www.ddnotesmaker.com/ADMP

##### recent news/filings ~ source: finance.yahoo.com

Tue, 01 Apr 2014 20:43:26 GMT ~ ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina
read full: http://biz.yahoo.com/e/140401/admp8-k.html
*********************************************************

Fri, 28 Mar 2014 10:00:00 GMT ~ 3 Biotech Stocks Under $10 to Trade for Breakouts
read full: http://www.thestreet.com/story/12558139/1/3-biotech-stocks-under-10-to-trade-for-breakouts.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Wed, 12 Mar 2014 21:28:45 GMT ~ ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
read full: http://biz.yahoo.com/e/140312/admp8-k_a.html
*********************************************************

Thu, 20 Feb 2014 18:04:08 GMT ~ ADAMIS PHARMACEUTICALS CORP Financials
read full: http://finance.yahoo.com/q/is?s=admp
*********************************************************

Fri, 14 Feb 2014 21:39:51 GMT ~ ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/140214/admp10-q.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ADMP/company-info
Ticker: $ADMP
OTC Market Place: Not Available
CIK code: 0000887247
Company name: Adamis Pharmaceuticals Corp.
Company website: http://www.adamispharmaceuticals.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000887247&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/ADMP/filings
Latest financials: http://www.otcmarkets.com/stock/ADMP/financials
Latest news: http://www.otcmarkets.com/stock/ADMP/news - http://finance.yahoo.com/q/h?s=ADMP+Headlines

Major holdings: http://data.cnbc.com/quotes/ADMP/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ADMP+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ADMP.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ADMP

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=ADMP&search=search

DTCC: http://search2.dtcc.com/?q=Adamis+Pharmaceuticals+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Adamis+Pharmaceuticals+Corp.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Adamis+Pharmaceuticals+Corp.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.adamispharmaceuticals.com
Alexa: http://www.alexa.com/siteinfo/http://www.adamispharmaceuticals.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.adamispharmaceuticals.com

Short Sales: http://www.otcmarkets.com/stock/ADMP/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ADMP/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ADMP/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ADMP+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ADMP+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ADMP+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ADMP+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ADMP+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ADMP+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ADMP
Balance Sheet: http://finance.yahoo.com/q/bs?s=ADMP
Cash Flow: http://finance.yahoo.com/q/cf?s=ADMP+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ADMP
Bloomberg: http://www.bloomberg.com/quote/ADMP:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ADMP
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ADMP
Barchart: http://www.barchart.com/quotes/stocks/ADMP
OTC Short Report: http://otcshortreport.com/index.php?index=ADMP
Investopedia: http://www.investopedia.com/markets/stocks/ADMP/?wa=0

http://www.pennystocktweets.com/stocks/profile/ADMP

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: 10,469,987 a/o Feb 03, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

##### business description ~ source: otcmarkets.com

IC

DD Notes ~ http://www.ddnotesmaker.com/ADMP

[Xzibit]

ADMP

[phishtrick]

$VCTY$ Jolly Roger double bagger IMO. Came to life today.

[carp1]

SSN Chart How did that hammer work out?

[trade2much]

Hi PT - nothing much going on from what I see, bio sector still getting hit so unless you have near by 4-6wks or less catalysts then usually the stock is dipping even with PDUFAs etc.

As Noah said "this too shall pass" ( but under his breath said "wish it would hurry up though")

Most everything I frequently trade is $13 or less, just not much ++ yet during the last few sessions, more stops than anything else, for know it is mostly conserve capital and wait out the storm.

If I see something worthwhile I will shoot up an annotated chart on it.


Lousy weather here: 39F and rainy- at least I don't have to shovel it, so that is a plus.

How's it where you are?


BOL
T2M

[Psionic Trader]

$QCOR got some just now $61.62

[trade2much]

PT - I have some ADMP and I am waiting 2. IDRA I was veryyyyy temped over the last few session but held off mostly due to the market and man it has dipped, so on that one decision I saved some $$.

Had a bunch of PDUFA stuff but in the out months so I am slowly lightening the load, the world events are not being nice to the Market and things with highly speculative value are getting whacked worst. (cheap bios)

The market always worries about something but with the Crimea up in the air and many former Soviet states. Now those same very small countries, in the area, have NATO Defense treaties. If they are attacked it could well draw the NATO's forces in. Putin is a nationalist and ex head of the KGB, he gives a Rat's a.. about what is good or fair etc etc, simply a dictator like many, trying to disguise himself as a diplomat. So he smells blood in the water and will test weakness and that will screw up the markets.

Just one of many worries we have as line after line is drawn in the sand and then erased, same type of process as the health care act is going through, exceptions and delays of deadlines.

Consequently at home and abroad we are somewhat screwed unless things change very soon. Oh well tomorrow is apt to be like yesterday so I guess we are in for more of the same BS.

Not too much to brag about in this market that is for sure, unless you were short bios lol, (I was not)

Bought a bit of SPSX 3x short the S&P index. It is an ETF with a daily range of a buck, so you can have fairly tight stops on it and it straddles a bit some of my long positions indirectly. (that is the theory at least, lol) Just in case we slide further.



T2M

[Psionic Trader]

seems CIMT got beaten down as of late and so I bought more. SGLB been my only green lol

Sold EXAS too early mostly. Looks like I should've held but didn't wanna hold through the event in case it drops like 40%.

How do you like IDRA? I got some ADMP due to the tight bollies and probably will add if it drops a bit within a defined range.

There's talk of gold being bottomed out for now.

[trade2much]

Hi PT, GM - yes it is 11F or was when I got up, but the sun is getting much higher in the sky so it warms nicely. Just a longgggggg winter and even longer for you, I would guess. We like x country, snowshoeing, etc but man after a while enough already. lol Almost Golf time.

The market is not pretty at this point and the bio sector has gotten slammed quite badly. I am lightening $$$ up for the Spring out and Fall in effect we get on many years.

Anything in particular you like know? Most of mine now are pink to red accept for a couple of penny stocks.


BOL

[Psionic Trader]

Lol I replied yesterday but browser hung after spotty Internet connection...

Is it still cold where you live? Is freezing. Never expected another snow but weather is as unpredictable as the stock market. Lol

[trade2much]

Psionic T - I can use some quick 2 baggers in this down bio market so I thought I would stop buy and see what's on your board for near term favorites in a downish market.

Glad we missed today's NEer, would not have been pretty to be on the cape today. We just got 20-25knot gusts. Where o where is Spring?



Hope all is well,

BOL

T2M

[Xzibit]

3D Printer plays will be HOT! IMHO

[Psionic Trader]

CIMT $7.34 on alert here. 3D printing play. Sitting nicely on top of 200ma

[surge1k]

TRDX .0009X.0011

[BottomBounce]

$ZAAP ZAP designs, develops, manufactures and sells electric and advanced technology vehicles. The Company has jointly developed an electric version of Zhejiang Jonway Automobile Co. Ltd (Jonway) A380 SUV, and plans to sell this vehicle in China and internationally. ZAP Jonway also intends to continue its production of conventional fuel vehicles and to expand its distribution network in both China and internationally. ZAP Jonway also intends to market its vehicles to government and corporate fleets. ZAP Jonway partners with Better World International Limited in the providing of electric charge station. Jonway's automotive product line includes the gas fueled A380 Five-Door SUV and the A380 Three-Door SUV. ZAP's automotive product line includes the all-electric E-380 SUV and the E-380 which supports swappable lithium batteries.

[Psionic Trader]

$SGLB rockin it today! up 20% 3D Print play

[Xzibit]

OREX looks like she is getting ready for a reversal

[Psionic Trader]

$OREX / $QRXPY holding in at $7.23 / $3.93 respectively

[Psionic Trader]

$ADMP in @ $6.72 holding and adding more...


Adamis Pharmaceuticals. Recently uplisted to NASDAQ. Market cap $62M

ADMP -> CRT capital group initiated with buy recently and $15 PT REPORT and some of the catalyst reported are here:

Some key points from report: "Having recently acquired the exclusive rights to 3M’s multi-dose dry powder inhaler (DPI),we believe there is the potential for Adamis to develop a competing product to GSK’s Advair Diskus by 2017."

* " In addition, the Company plans on filing an epinephrine pre-filled syringe (forthe treatment of anaphylaxis) product by Q1’14, which could be commercialized by year end."

• In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.

• By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of

this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M.

• By mid’14, we believe Adamis will look to meet with the FDA to discuss its development plans on APC-1000 (beclomethasone inhaler - comparable to TEVA’s QVAR). We believe Adamis has plans to run a Phase 3 study evaluating the efficacy of its product vs. Qvar. On this product, Adamis is partnered with Beximco.

• By late 2014, we believe Adamis could secure additional partners for its Taper Dry Powder Inhaler for international markets. We would not rule out Adamis also looking for potential partners for its APC-1000 beclomethasone product.

Full report can be found here: https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=97574609&txt2find=admp

[Enterprising Investor]

AOBI: "Beer Money" trade

Buy 500 shares. Approve "Going Private" transaction. Get $.50 per share.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94411767

[Psionic Trader]

$LJPC Phase2a estimated primary completion date: March 2014

The primary objective of this study is to compare the change in estimated glomerular filtration rate (eGFR) from baseline to Week 8 between placebo and GCS-100 treatment. The secondary objective is to determine the safety and tolerability of GCS-100 administered for 8 weeks relative to placebo. In addition, the study will measure the effect of GCS-100 on circulating galectin-3 and other markers of disease activity.

http://www.clinicaltrials.gov/ct2/show/record/NCT01843790?term=gcs-100&rank=3

[Psionic Trader]

$LJPC $7.80 afterhours. $7.94 at ask.

[Psionic Trader]

$OREX got some more and adding on any dips. June PDUFA

[Psionic Trader]

$ATOS $2.29 back down from mid day highs, added more on this dip. 510k Notification mid March. low volume drop and most indicators reset & coiled.

http://finance.yahoo.com/news/atossa-genetics-submits-premarket-510-133000889.html

[Psionic Trader]

CHTP in long options march strangle ... hoping for a big move next week. Could be an awesome valentines day gift!

[Psionic Trader]

86% is the magic number...

According to a McKinnsey Study based on approval of drugs between 2001 and 2010, whopping 86% of the time the FDA would approve on AdCom positive suggestion, Study states that it also depends a bit on other factors too such as sensitity/specificity, meetings, and 'number of days' it took to get there.

FDA Advisory Commitee Outcomes

McKinsey Center for Government
FDA Advisory
Committee Outcomes
Philip Ma, Navjot Singh, Jeff Smith, Seth Townsend
FDA Advisory
Committee Outcomes
FDA advisory committee meetings are high-stakes interactions, with many years of effort,
millions of dollars of investment, potential regulatory approval, and billions of dollars in
potential sales for a new drug riding on the outcome. We have analyzed publicly available
data and established a fact base that provides all stakeholders with a better characterization
and greater transparency into the outcomes of advisory committee meetings. We also
consider the implications for how sponsors can use this information to improve R&D
decision-making.
During the pre-market review process for drugs
and medical devices, many regulatory agencies
seek unbiased advice from external experts to
address areas of scientific or technical uncertainty.
The US Food and Drug Administration (FDA) in
particular has a well-defined process for obtaining
expert input from its advisory committees and
incorporating the input into its review processes.
FDA reviewers complete an initial review of a
product application and identify questions where
external input is needed. The FDA then convenes
an advisory committee meeting and obtains
the requested input through a combination
of presentations, discussion, and voting by
committee members. After the meeting, FDA
reviewers take into account the input received
when making product approval decisions,
although the recommendations of the committee
are not binding.
FDA advisory committee meetings are high-stakes
interactions, with many years of effort, millions
of dollars of investment, potential regulatory
approval, and billions of dollars in potential sales
for a new drug riding on the outcome. However,
despite the fact that sponsors recognize the
crucial nature of these meetings and are familiar
with the processes, we have found limitations in
the quantitative understanding of their outcomes.
In this article, we have analyzed publicly available
data on FDA advisory committee meetings with
the aim of helping to address these limitations. We
investigated several important issues, including
the total number of meetings by type and
therapeutic area, the frequency with which new
product applications are subjected to advisory
committee meetings, consistency between the
advisory committee votes and FDA approval
decisions, and the duration between an advisory
committee meeting and the final FDA approval
date for a product.
1
Exhibit 1 | Characteristics of FDA advisory committee meetings between 2001 and 2010.
All other
meetings (262)
AC meetings
for drugs
2001–2010 (543)
Original NDAs
or BLAs (190)
NDA- or BLA-
focused
meetings (281)
Voting on approval
question (63)
c 50
Voting, all others (70)
No voting (57)
Supplemental
NDAs or BLAs (91)
Voting, all others (26)
43.8
35.9
32.8
Voting on approval
question (22)
43.8
41.4
40
a
42.9
35.2
31.6
0 37.0
30
20
No voting (43)
b
10
8.2%
8.2%
M
lN
7.5%
13.5%
6.4%
Al
281
meetings
0
??Oncological drugs AC
??Cardiovascular and renal drugs AC
??Anti-infective drugs AC
??Endocrinological and metabolic drugs AC
??Antiviral drugs AC
??Psychopharmacological drugs AC
??Arthritis AC
??All others
5.3%
21.4%
29.5%
All NMEs (2001–2010)
??Date
??Molecule type
??Priority status
??Orphan status
a | Overall characteristics of 543 US Food and Drug Administration (FDA) advisory committee (AC) meetings held for drugs between 2001 and 2010.
b | Distribution by committee of the 281 meetings focused on new drug applications (NDAs) or biologics license applications (BLAs).
c | Percentage of approved new molecular entities (NMEs) that were the subject of an AC meeting. NBE, new biological entity; NCE, new chemical entity.
Analysis
We conducted an outside-in analysis of the
outcomes of FDA advisory committee meetings
held for drugs during the decade from 2001
to 2010 by reviewing publicly accessible
materials, including meeting minutes, posted
on the FDA’s website.
32.8% in the 2001–2005 period to 41.4% in the
2006–2010 period, suggesting a slight increase
in the FDA’s use of advisory committee input to
help inform product approval decisions. Additional
data analysis shows that new biologics, priority
status applications, and orphan drugs were the
subject of more meetings, on a percentage basis,
than new chemical entities, standard applications,
and non-orphan drugs.
Of the 543 total advisory committee meetings
held for drugs in the 2001-2010 period (Exhibit
1a), 281 were focused on a single product, of
which 190 were for original new drug applications
(NDAs) and biologics license applications (BLAs),
and 91 were for supplemental NDAs or BLAs.
The distribution of meetings by therapeutic area
is shown in Exhibit 1b. With regard to novel drugs,
37% of FDA-approved new chemical entities or
new biological entities in the 2001–2010 period
were the subject of an advisory committee meeting
(Exhibit 1c). This percentage increased from
We considered in detail a subset of 63 of the 190
meetings related to original NDAs or BLAs, at
which committee members were asked to vote
for or against approval of the drug of interest. In
the analysis, we looked at the voting record to
determine whether the committee provided an
endorsement for the approval of the drug (identi-
fied as a simple majority of votes recommending
approval). We then identified whether the FDA
2
Exhibit 2 | Analysis of a subset of 63 FDA advisory committee meetings that included votes for or against the
approval of a new drug between 2001 and 2010.
2
12
Yes
b 80
68.2
70
c 800
700
60
50
40
30
20
19.1
12.7
10
0
699
600
6
43
Sensitivity: 95.6% Specificity: 66.7%
Percentage of meetings
a
500
400
300
191
200
140
100
=33
33–67
=67
0
=33
33–67
=67
No
Did the FDA approve the product?
Percentage of advisory committee
vote in favour of approval
Percentage of advisory committee
vote in favour of approval
a | Summary of US Food and Drug Administration (FDA) advisory committee recommendations and approval decisions.
b | Clarity of outcome of voting decisions. We considered the effect of the strength of the advisory committee endorsement by creating three equal
categories: =33% endorsement for approval; between 33% and 67% endorsement for approval; and =67% endorsement for approval. In 87% of
committee meetings, the result was either a clear “yes” or “no” vote.
c | Association between the strength of the endorsement by the advisory committee, as measured by the percentage of panel members voting for
approval, and the median duration between the meeting and the FDA approval date. The duration varies inversely with the strength of the endorsement.
approved the drug, and for those drugs that were
approved we also identified the duration of time
between the meeting and the approval date.
Exhibit 2b shows that in 87% of committee
meetings the result was either a clear “yes”
or “no” vote. One possible explanation for this
observation is that the committee members
have a deep expertise in their field and can
readily address the areas of uncertainty in the
application. An alternative explanation could be a
“herding effect” in advisory committee meetings,
where one or more influential members convince
other panel members of their point of view. The
open, role-call voting system of most meetings
could further contribute to this effect. In practice,
it seems likely that both explanations contribute
to this observation.
As shown in Exhibit 2a, the FDA’s approval
decisions have been broadly consistent with the
recommendations of its advisory committees.
The FDA approved 88% of the original NDAs
or BLAs that were endorsed by its advisory
committees, and did not approve 86% of
those that the committees did not endorse. In
addition, in those instances when the approval
decision made by the FDA differed from the
recommendation of the advisory committee,
the FDA did so at the same rate regardless
of whether the panel endorsed approval. The
sensitivity and specificity of advisory committee
recommendations as a test for FDA approval is
96% and 67%, respectively. In addition, at 78%
of advisory committee meetings the members
recommended drug approval.
The association between the strength of the
endorsement by the committee (as measured
by the percentage of panel members voting for
approval) and the duration between the advisory
committee meeting and FDA approval date is
shown in Exhibit 2c. As might be anticipated,
3
the duration varies inversely with the strength
of the endorsement, suggesting that strongly
endorsed products tend to be approved on the
first review cycle, whereas products that are not
as strongly endorsed could be associated with
multiple review cycles. Our results also show
that advisory committees endorse approximately
the same percentage of products for approval
as the FDA approves applications (~75%). This
suggests that the FDA is not disproportionately
pre-screening either clear approvals or rejections
prior to selecting applications to review at an
advisory committee meeting. Instead, the
results are suggestive of a two-cohort model of
applications based on whether FDA reviewers
feel they have sufficient input and knowledge to
make approval decisions without an advisory
committee meeting. This supports the notion
that advisory committees have a crucial role
in providing necessary input to FDA reviewers
during the pre-market review process.
Implications
We believe that these results have important
implications for companies that are preparing for
potential advisory committee meetings. Given
the characteristics of advisory committees
that we have described here, we believe that
the use of bodies akin to advisory committees
could be considerably expanded by industry,
and could be a major driver for improved
decision-making. Companies currently use
mock advisory panels to help rehearse and
prepare for advisory committee meetings.
However, given the sensitivity and specificity of
the approach, companies may be better served
by incorporating the approach into decision-
making, not merely preparation. This could be
applied at different points in the life cycle of a
product where important investment decisions
are made—for example, following Phase II
development—in addition to pre-submission.
Editor’s note: This article was previously published
in Nature Reviews Drug Discovery.
4
McKinsey Center for Government
October 2013
Layout by US Design Center
Copyright © McKinsey & Company
www.mckinsey.com/mcg

[Psionic Trader]

$BIS biotech short ETF was up 6% earlier and now around 4-5%. The only thing green in my account today lol

[Psionic Trader]

$DARA chart has almost nearly reset and in my eyes it's looking quite yummy but using stops whenever possible. I'm gonna start thinking about taking some action to consider a possibility of contemplating a thought of making the move to lean towards positioning myself to possibly have an affinity in the action of taking a starter position. :)

Probably getting some at 0.5s or when StochRSI begins to get out of the lower zone. Not sure what to make of the ADX though but the golden cross can't be a bad thing.

[Psionic Trader]

$BIS biotech short. Adding some more to hedge against biotech overbought conditions, just in case. Increased volume with what appears to be a bottoming formation as of late may signal something. It doesn't seem to have noticeable large gaps in the chart, so stop order utilization would be a tad safer. (ie: little chance of surprise gap down that renders stops useless, when we wake up one morning)

[Psionic Trader]

$CHTP looking at the chart concerned it may be losing $4.50s support? ADX not looking too promising either. But then there's the fda event next week so maybe it'll hold up and run for a bit.

[Xzibit]

GMTA Psi Love me some microsoft I could see it trading @ $100 in the not to distant future easily, Bing, Xbox, Skype, Nokia, Windows 8 used in tablets, microsoft office, word, excel etc.....

Bill Gates keeps up with the times he is not asleep at the wheel like Apple CEO is

[Psionic Trader]

Msft is most likely a runner from here possibly 20%+ gains in the near future , there's a reverse head and shoulders pattern that formed recently meaning it's bottomed out and ready to run

[Xzibit]

There is always a champion in the stock market.


One of my favorite long term stocks is none other than MSFT, Bill

has Bing, Skype Windows 8, Nokia Lumia 41 megapixelcamera/cellphone,

Internet Explorer, Xbox. Did I miss anything

[Psionic Trader]

That Is interesting..

[InvestorSuisse]

HCTI Very Interesting Information..

Obama Action Plan Mentions Hybrid's Technology as Alternative to Toxic Polyurethane Coatings.. HUGE..
http://www.hybridcoatingtech.com/pdf/US-EPA-Issues-Action-Plan-to-Deal-With-Toxic-Isocyanates-July1.pdf

[Psionic Trader]

LL Lumber liquidators chart is set. Strong valuations

[Psionic Trader]

CHTP $5 Call options for March. Added

[Psionic Trader]

Got some apple after hours

[InvestorSuisse]

ALAS is setting up nicely, its majorly undervalued as I mentioned a few weeks ago. ALAS printed a high today of 0.17, this is only the beginning.

Ive been telling everyone not to miss this great opportunity.